000661 长春高新
交易中 07-23 10:01:45
资讯
新帖
简况
长春高新（000661）股东长春超达投资集团有限公司质押2083万股，占总股本5.15%
证券之星 · 07-20
长春高新（000661）股东长春超达投资集团有限公司质押2083万股，占总股本5.15%
长春高新(000661.SZ)控股股东质押2083万股
智通财经 · 07-19
长春高新(000661.SZ)控股股东质押2083万股
长春高新(000661.SZ)终止实施2022年限制性股票与股票期权激励计划
智通财经 · 07-19
长春高新(000661.SZ)终止实施2022年限制性股票与股票期权激励计划
长春高新最新公告：重组人促卵泡激素-CTP融合蛋白注射液上市申请获受理
证券之星 · 07-18
长春高新最新公告：重组人促卵泡激素-CTP融合蛋白注射液上市申请获受理
长春高新(000661.SZ)：重组人促卵泡激素-CTP融合蛋白注射液上市申请获得受理
智通财经 · 07-18
长春高新(000661.SZ)：重组人促卵泡激素-CTP融合蛋白注射液上市申请获得受理
长春高新（000661）7月17日主力资金净卖出484.65万元
证券之星 · 07-18
长春高新（000661）7月17日主力资金净卖出484.65万元
长春高新(000661.SZ)控股股东解除质押其所持5.15%公司股份
智通财经 · 07-17
长春高新(000661.SZ)控股股东解除质押其所持5.15%公司股份
长春高新：公司下属子公司各BU积极推进现有产品销售工作，具体产品销售数据等情况请关注公司定期报告等
证券之星 · 07-11
长春高新：公司下属子公司各BU积极推进现有产品销售工作，具体产品销售数据等情况请关注公司定期报告等
长春高新：对于溴夫定片，公司子公司与相关生产企业在部分地区采用CSO模式进行合作
证券之星 · 07-07
长春高新：对于溴夫定片，公司子公司与相关生产企业在部分地区采用CSO模式进行合作
长春高新：感谢您对公司的建议，我们会将您的意见转达给经营管理层
证券之星 · 07-04
长春高新：感谢您对公司的建议，我们会将您的意见转达给经营管理层
长春高新(000661.SZ)控股子公司黄体酮注射液(II)获得药品注册证书
智通财经 · 06-25
长春高新(000661.SZ)控股子公司黄体酮注射液(II)获得药品注册证书
长春高新最新公告：控股子公司黄体酮注射液（II）获得药品注册证书
证券之星 · 06-25
长春高新最新公告：控股子公司黄体酮注射液（II）获得药品注册证书
长春高新最新公告：选举姜云涛为董事长、总经理
证券之星 · 06-24
长春高新最新公告：选举姜云涛为董事长、总经理
长春高新最新公告：自愿承诺未来六个月内不减持子公司百克生物股份
证券之星 · 06-24
长春高新最新公告：自愿承诺未来六个月内不减持子公司百克生物股份
诸茅的落寞时刻，有多惨？
格隆汇 · 06-23
诸茅的落寞时刻，有多惨？
长春高新：公司会综合考虑未来发展规划、实际经营情况、股东诉求等合理拟定分红方案
证券之星 · 06-19
长春高新：公司会综合考虑未来发展规划、实际经营情况、股东诉求等合理拟定分红方案
长春高新最新公告：子公司获得医疗器械注册证
证券之星 · 06-17
长春高新最新公告：子公司获得医疗器械注册证
长春高新(000661.SZ)下属公司获得医疗器械注册证
智通财经 · 06-17
长春高新(000661.SZ)下属公司获得医疗器械注册证
长春高新分红率仅17%市值三年蒸发1600亿 受集采影响净利失速首季增速仅0.2%
市场资讯 · 06-03
长春高新分红率仅17%市值三年蒸发1600亿 受集采影响净利失速首季增速仅0.2%
长春高新：公司积极推进亮丙瑞林注射乳剂用于晚期前列腺癌、绝经前乳腺癌等方面的研发工作
证券之星 · 06-02
长春高新：公司积极推进亮丙瑞林注射乳剂用于晚期前列腺癌、绝经前乳腺癌等方面的研发工作
加载更多
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品为聚乙二醇重组人生长激素注射液、重组人生长激素、注射用重组人促卵泡激素、冻干水痘减毒活疫苗、人用狂犬病疫苗、血栓心脉宁片、银花泌炎灵片等。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":92.78,"timestamp":1721700105000,"preClose":94.66,"halted":0,"volume":1193800,"delay":0,"floatShares":398000000,"shares":404000000,"eps":11.2116,"marketStatus":"交易中","marketStatusCode":2,"change":-1.88,"latestTime":"07-23 10:01:45","open":94.29,"high":94.34,"low":92.76,"amount":111000000,"amplitude":0.0167,"askPrice":92.77,"askSize":31,"bidPrice":92.76,"bidSize":4,"shortable":0,"etf":0,"ttmEps":11.2116,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1721705400000},"adr":0,"adjPreClose":94.66,"symbolType":"stock","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":104.13,"lowLimit":85.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":404423090,"pbRate":1.68,"roa":"--","roe":"3.83%","epsLYR":11.21,"committee":-0.172932,"marketValue":37522000000,"floatMarketCap":36967000000,"peRate":8.275357,"changeRate":-0.0199,"turnoverRate":0.003,"status":1},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2452047282","title":"长春高新（000661）股东长春超达投资集团有限公司质押2083万股，占总股本5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452047282","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452047282?lang=zh_cn&edition=full","pubTime":"2024-07-20 03:25","pubTimestamp":1721417123,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新7月20日公开信息显示，股东长春超达投资集团有限公司向吉林银行股份有限公司长春新区支行合计质押2083.0万股，占总股本5.15%。质押详情见下表：截止本公告日，股东长春超达投资集团有限公司已累计质押股份3803.0万股，占其持股总数的49.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072000005301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","000661","BK0075","BK0239","BK0057","BK0188"],"gpt_icon":0},{"id":"2452429002","title":"长春高新(000661.SZ)控股股东质押2083万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452429002","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452429002?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:04","pubTimestamp":1721387089,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，公司于近日收到控股股东长春超达投资集团有限公司(简称“超达集团”)关于其部分股份质押的通知，本次质押2083万股，占公司总股本比例的5.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0046","BK0028","BK0188","BK0057","BK0239","BK0075"],"gpt_icon":0},{"id":"2452142949","title":"长春高新(000661.SZ)终止实施2022年限制性股票与股票期权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2452142949","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452142949?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:02","pubTimestamp":1721386962,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，公司审议通过了《关于终止实施2022年限制性股票与股票期权激励计划暨回购注销限制性股票及注销股票期权的议案》，经审慎研究，并结合激励对象意愿，公司拟终止实施2022年限制性股票与股票期权激励计划，回购注销本次激励计划剩余已授予但尚未解除限售的限制性股票并注销本次激励计划剩余已授予但尚未行权的股票期权，与之配套的《2022年限制性股票与股票期权激励计划管理办法》《2022年限制性股票与股票期权激励计划实施考核管理办法》等相关文件一并终止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0057","BK0239","BK0075","BK0028","000661","BK0188","BK0046"],"gpt_icon":0},{"id":"2452488941","title":"长春高新最新公告：重组人促卵泡激素-CTP融合蛋白注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452488941","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452488941?lang=zh_cn&edition=full","pubTime":"2024-07-18 20:00","pubTimestamp":1721304040,"startTime":"0","endTime":"0","summary":"长春高新公告，控股子公司金赛药业的药品重组人促卵泡激素-CTP融合蛋白注射液的境内生产药品注册上市许可申请获得受理。金赛药业开发的重组人促卵泡激素-CTP融合蛋白注射液（FSH-CTP）是注册分类3.2的治疗用生物制品，拟用于女性在接受辅助生殖技术（ART）治疗时，进行控制性卵巢刺激（COS）以促进多个卵泡发育。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800041522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0075","BK0028","000661","BK0188","BK0046"],"gpt_icon":0},{"id":"2452104676","title":"长春高新(000661.SZ)：重组人促卵泡激素-CTP融合蛋白注射液上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452104676","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452104676?lang=zh_cn&edition=full","pubTime":"2024-07-18 19:08","pubTimestamp":1721300929,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司控股子公司长春金赛药业有限责任公司(“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》。据悉，金赛药业开发的重组人促卵泡激素-CTP融合蛋白注射液(FSH-CTP)是注册分类3.2的治疗用生物制品，拟用于女性在接受辅助生殖技术(ART)治疗时，进行控制性卵巢刺激(COS)以促进多个卵泡发育。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","000661","BK0188","BK0057","BK0046","BK0075"],"gpt_icon":0},{"id":"2452148674","title":"长春高新（000661）7月17日主力资金净卖出484.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452148674","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452148674?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:15","pubTimestamp":1721265316,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月17日收盘，长春高新报收于94.96元，上涨1.91%，换手率1.33%，成交量5.36万手，成交额5.07亿元。近5日资金流向一览见下表：长春高新融资融券信息显示，融资方面，当日融资买入6251.02万元，融资偿还7183.78万元，融资净偿还932.76万元。长春高新主营业务：生物制药及中成药的研发、生产和销售,辅以房地产开发、物业管理和服务等业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800014199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0075","BK0057","000661","BK0028","BK0239"],"gpt_icon":0},{"id":"2452158039","title":"长春高新(000661.SZ)控股股东解除质押其所持5.15%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2452158039","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452158039?lang=zh_cn&edition=full","pubTime":"2024-07-17 19:52","pubTimestamp":1721217136,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，公司于近日收到控股股东长春超达投资集团有限公司(“超达集团”)关于其部分股份解除质押的通知，其本次解除质押2083万股，占其所持股份27.32%，占总股本5.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0188","BK0239","BK0057","BK0046","BK0028","BK0075"],"gpt_icon":0},{"id":"2450358486","title":"长春高新：公司下属子公司各BU积极推进现有产品销售工作，具体产品销售数据等情况请关注公司定期报告等","url":"https://stock-news.laohu8.com/highlight/detail?id=2450358486","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450358486?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:02","pubTimestamp":1720695738,"startTime":"0","endTime":"0","summary":"半年报跟去年比如何，会不会因研发和销售费用增加，导致利润下降长春高新董秘：您好，公司管理层持续努力做好经营管理工作，如有重要经营信息会及时按照法律法规要求履行披露义务，半年度数据请关注公司后续定期报告等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100036416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0075","BK0239","BK0057","BK0188","BK0046","BK0028"],"gpt_icon":0},{"id":"2449766828","title":"长春高新：对于溴夫定片，公司子公司与相关生产企业在部分地区采用CSO模式进行合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2449766828","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449766828?lang=zh_cn&edition=full","pubTime":"2024-07-07 23:00","pubTimestamp":1720364432,"startTime":"0","endTime":"0","summary":"长春高新董秘：国内外药典均认为，抑菌剂的添加对注射剂的安全性是必要的，除非产品本身具有重组的抗菌性质，否则多次使用注射液应含有适当浓度合适的抑菌剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070700002260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0046","BK0028","BK0188","BK0239","BK0057"],"gpt_icon":0},{"id":"2448175474","title":"长春高新：感谢您对公司的建议，我们会将您的意见转达给经营管理层","url":"https://stock-news.laohu8.com/highlight/detail?id=2448175474","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448175474?lang=zh_cn&edition=full","pubTime":"2024-07-04 17:03","pubTimestamp":1720083810,"startTime":"0","endTime":"0","summary":"投资者：公司借款给大股东，获得公司股东会议同意没有长春高新董秘：您好，公司严格按照法律法规要求履行重大事项的相应审议程序，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400033923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0075","000661","BK0057","BK0028","BK0046"],"gpt_icon":0},{"id":"2446101038","title":"长春高新(000661.SZ)控股子公司黄体酮注射液(II)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446101038","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446101038?lang=zh_cn&edition=full","pubTime":"2024-06-25 20:21","pubTimestamp":1719318063,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司控股子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药品注册证书》，现将相关审批结论公告如下：“根据《中华人民共和国药品管理法》及有关规定，经审查，黄体酮注射液(II)1.112ml:25mg符合药品注册的有关要求，批准注册，发给药品注册证书。”批准的适应症为：“用于辅助生殖技术(ART)中黄体酮的补充治疗，适用于不能使用或不能耐受阴道制剂的女性”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0239","BK0075","BK0188","000661","BK0028","BK0057"],"gpt_icon":0},{"id":"2446848811","title":"长春高新最新公告：控股子公司黄体酮注射液（II）获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446848811","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446848811?lang=zh_cn&edition=full","pubTime":"2024-06-25 20:20","pubTimestamp":1719318011,"startTime":"0","endTime":"0","summary":"长春高新公告，控股子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药品注册证书》，黄体酮注射液（II）1.112ml:25mg符合药品注册的有关要求，批准注册，发给药品注册证书。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500039713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0075","BK0028","000661","BK0188","BK0046"],"gpt_icon":0},{"id":"2445743500","title":"长春高新最新公告：选举姜云涛为董事长、总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2445743500","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445743500?lang=zh_cn&edition=full","pubTime":"2024-06-24 21:20","pubTimestamp":1719235237,"startTime":"0","endTime":"0","summary":"长春高新公告，选举姜云涛为公司第十一届董事会董事长，任期三年，自本次董事会审议通过之日起至第十一届董事会届满之日为止。同意聘任姜云涛为公司总经理。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400032498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","000661","BK0075","BK0239","BK0057","BK0188"],"gpt_icon":0},{"id":"2445765710","title":"长春高新最新公告：自愿承诺未来六个月内不减持子公司百克生物股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2445765710","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445765710?lang=zh_cn&edition=full","pubTime":"2024-06-24 20:30","pubTimestamp":1719232250,"startTime":"0","endTime":"0","summary":"长春高新公告，基于对百克生物未来发展前景的信心及投资价值的认可，公司自愿承诺自2024年6月25日至2024年12月24日期间不减持所持有的百克生物股份。在上述承诺期内，如百克生物发生送红股、转增股本、配股等增加的股份亦遵守上述承诺。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400030793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276","BK0046","000661","BK0057","BK0188","BK0028","BK0075"],"gpt_icon":0},{"id":"2445039778","title":"诸茅的落寞时刻，有多惨？","url":"https://stock-news.laohu8.com/highlight/detail?id=2445039778","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445039778?lang=zh_cn&edition=full","pubTime":"2024-06-23 16:40","pubTimestamp":1719132041,"startTime":"0","endTime":"0","summary":"腰斩不止，依旧无人问津","market":"sg","thumbnail":"https://img3.gelonghui.com/02e7b-d4ae3b25-eb39-47f4-bf23-e8b4404418ca.png?guru_height=376&guru_width=640","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/02e7b-d4ae3b25-eb39-47f4-bf23-e8b4404418ca.png?guru_height=376&guru_width=640"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/807364","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0229","BK0284","000661","BK0096","BK1161","300896","BK0060","600276","BK0012","BK1515","09939","BK0046","BK0238","BK1574","BK0057","BK0146","002507","BK0114","LU1997245177.USD","LU1997245094.SGD","LU1146622755.USD","BK0196","600763","LU1064130708.USD","BK0048","603288","BK0075","LU0979878070.USD","LU2148510915.USD","603605","BK0226","LU1064131003.USD","LU1242518857.USD","LU0405327494.USD","688076","LU1820825898.SGD","BK0183","BK0188","LU1328615791.USD","603517","BK0077","BK0236","300122","BK0251","LU0405327148.USD","LU0593848301.USD","BK0175","LU1242518931.SGD","BK0028","688363"],"gpt_icon":0},{"id":"2444219904","title":"长春高新：公司会综合考虑未来发展规划、实际经营情况、股东诉求等合理拟定分红方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2444219904","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444219904?lang=zh_cn&edition=full","pubTime":"2024-06-19 18:04","pubTimestamp":1718791450,"startTime":"0","endTime":"0","summary":"长春高新董秘：公司子公司百克生物带状疱疹疫苗已经上市销售，暂无具体市场占有率数据，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900036344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0046","BK0028","BK0188","BK0239","BK0057"],"gpt_icon":0},{"id":"2444316377","title":"长春高新最新公告：子公司获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2444316377","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444316377?lang=zh_cn&edition=full","pubTime":"2024-06-17 19:20","pubTimestamp":1718623243,"startTime":"0","endTime":"0","summary":"长春高新公告，子公司上海赛增医疗科技有限公司收到上海市药品监督管理局颁发的《医疗器械注册证》(体外诊断试剂)，产品名称为胰岛素样生长因子结合蛋白3（IGFBP-3）检测试剂盒（荧光免疫层析法）。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700024153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK1583","BK1222","BK0188","BK1100","09996","000661","09997","BK0028","159883","BK0075","BK0046","BK0239","BK1574"],"gpt_icon":0},{"id":"2444163589","title":"长春高新(000661.SZ)下属公司获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2444163589","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444163589?lang=zh_cn&edition=full","pubTime":"2024-06-17 19:18","pubTimestamp":1718623086,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司下属公司上海赛增医疗科技有限公司收到上海市药品监督管理局颁发的《医疗器械注册证》(体外诊断试剂)。产品名称为胰岛素样生长因子结合蛋白3(IGFBP-3)检测试剂盒(荧光免疫层析法)，用于体外定量检测人血清中胰岛素样生长因子结合蛋白3(IGFBP-3)的含量，做辅助诊断用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK0046","BK0028","BK1583","BK1100","159883","09996","000661","BK1222","BK0075","BK0239","BK0057","BK0188","BK1574"],"gpt_icon":0},{"id":"2440102348","title":"长春高新分红率仅17%市值三年蒸发1600亿 受集采影响净利失速首季增速仅0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440102348","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440102348?lang=zh_cn&edition=full","pubTime":"2024-06-03 07:44","pubTimestamp":1717371840,"startTime":"0","endTime":"0","summary":" 有“东北药茅”之称的A股上市药企长春高新又被传闻利空，股价大跌。 5月30日，长春高新股价盘中突然大跌，收盘时跌幅6.05%。 曾经，长春高新备受资本追捧，前复权后，2021年5月17日，股价曾达515.90元/股，市值超过2100亿元。到今年5月31日，三年间，股价累跌近80%，市值蒸发了逾1600亿元。 长春高新的经营业绩也明显失速。2023年，公司净利润增速也是近年来首次降至个位数。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-06-03/doc-inaxmham4927454.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-06-03/doc-inaxmham4927454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0057","BK0239","BK0028","BK0046","BK0075","000661"],"gpt_icon":0},{"id":"2440141563","title":"长春高新：公司积极推进亮丙瑞林注射乳剂用于晚期前列腺癌、绝经前乳腺癌等方面的研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2440141563","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440141563?lang=zh_cn&edition=full","pubTime":"2024-06-02 18:00","pubTimestamp":1717322437,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新06月02日在投资者关系平台上答复投资者关心的问题。金赛药业官方英文网站上显示了与MAAB的合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060200001632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0075","BK0239","BK0057","BK0188","BK0046","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","stockEarnings":[{"period":"1week","weight":0.0352},{"period":"1month","weight":-0.0342},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.203},{"period":"1year","weight":-0.3159},{"period":"ytd","weight":-0.3257}],"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","perCapita":"3047股","boardName":"医药制造业","registeredCapital":"40442万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 长春高新技术产业(集团)股份有限公司的主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品为聚乙二醇重组人生长激素注射液、重组人生长激素、注射用重组人促卵泡激素、冻干水痘减毒活疫苗、人用狂犬病疫苗、血栓心脉宁片、银花泌炎灵片等。","serverTime":1721700106872,"listedPrice":8.8,"stockholders":"130749人(较上一季度增加3.04%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}